Structure-activity relationship study on Tyr9 of urotensin-II(4-11): Identification of a partial agonist of the UT receptor

被引:11
|
作者
Batuwangala, Madura [2 ,3 ]
Camarda, Valeria [2 ]
McDonald, John [3 ]
Marzola, Erika [1 ]
Lambert, David G. [3 ]
Ng, Leong L. [3 ]
Calo', Girolamo [2 ]
Regoli, Domenico [2 ]
Trapella, Claudio [1 ]
Guerrini, Remo [1 ]
Salvadori, Severo [1 ]
机构
[1] Univ Ferrara, Dept Pharmaceut Sci, I-44100 Ferrara, Italy
[2] Univ Ferrara, Pharmacol Sect, Dept Expt & Clin Med, I-44100 Ferrara, Italy
[3] Univ Leicester, Div Anaesthesia Pharmacol & Therapeut, Dept Cardiovasc Sci, Leicester LE2 7LX, Leics, England
关键词
Urotensin-II; UT receptor; Structure-activity study; Peptide synthesis; Ca2+ mobilization; Rat aorta; II-RELATED PEPTIDE; ANALOGS; LIGAND; URP; VASOCONSTRICTOR; ANTAGONISTS; URANTIDE; DOMAINS; DISEASE; MODEL;
D O I
10.1016/j.peptides.2009.02.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Urotensin-II (U-II) activates the U-II receptor (UT) to modulate a range of biological responses at both central and peripheral sites. Previous studies have demonstrated that the sequence Trp(7)-Lys(8)-Tyr(9) of the cyclic portion of the peptide is crucial for biological activity. Here, we describe a focused structure-activity study of Tyr(9) which has been replaced with a series of non-coded amino acids in the U-II(4-11) template. Thirteen analogs were synthesized and pharmacologically tested for intracellular calcium mobilization in HEK293 cells stably expressing the rat LIT receptor. The results of this study demonstrated the following Tyr9 structure-activity features: (i) the position of the OH group of the side chain is not important for biological activity, (ii) the distance of the phenol moiety from the peptide backbone and its conformational freedom are crucial for UT receptor recognition, (iii) this position is important not only for receptor occupation but also for its activation since the 3,5-diiodoTyr(9) chemical modification generated a potent partial agonist. This pharmacological activity of[3,5-diiodoTyr(9)]U-II(4-11) was confirmed in bioassay experiments performed using the rat thoracic aorta as a U-II sensitive preparation. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:1130 / 1136
页数:7
相关论文
共 50 条
  • [31] Factors influencing agonist potency and selectivity for the opioid δ receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl) arylamino]-N,N-diethylbenzamides
    Thomas, JB
    Herault, XM
    Rothman, RB
    Atkinson, RN
    Burgess, JP
    Mascarella, SW
    Dersch, CM
    Xu, H
    Flippen-Anderson, JL
    George, CF
    Carroll, FI
    JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (06) : 972 - 987
  • [32] A QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP STUDY ON SOME PYRAZOLO[4,5-C]QUINOLINES ACTING AS INHIBITORS OF BENZODIAZEPINE-RECEPTOR BINDING
    GUPTA, SP
    SAHA, RN
    GUPTA, JK
    SINGH, P
    RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, 1989, 65 (01): : 119 - 122
  • [33] Structure-Activity Relationship Study of the High-Affinity Neuropeptide Y4 Receptor Positive Allosteric Modulator VU0506013
    Schuess, Corinna
    Vu, Oanh
    Mishra, Nigam M.
    Tough, Iain R.
    Du, Yu
    Stichel, Jan
    Cox, Helen M.
    Weaver, C. David
    Meiler, Jens
    Emmitte, Kyle A.
    Beck-Sickinger, Annette G.
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (13) : 8745 - 8766
  • [34] Structure-Activity Relationship Study of a CXC Chemokine Receptor Type 4 Antagonist, FC131, Using a Series of Alkene Dipeptide Isosteres
    Kobayashi, Kazuya
    Oishi, Shinya
    Hayashi, Ryoko
    Tomita, Kenji
    Kubo, Tatsuhiko
    Tanahara, Noriko
    Ohno, Hiroaki
    Yoshikawa, Yasushi
    Furuya, Toshio
    Hoshino, Masaru
    Fujii, Nobutaka
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (06) : 2746 - 2757
  • [35] 2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study
    Basnet, Arjun
    Thapa, Pritam
    Karki, Radha
    Choi, Hoyoung
    Choi, Jae Hun
    Yun, Minho
    Jeong, Byeong-Seon
    Jahng, Yurngdong
    Na, Younghwa
    Cho, Won-Jea
    Kwon, Youngjoo
    Lee, Chong-Soon
    Lee, Eung-Seok
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (01) : 42 - 47
  • [36] Synthesis and structure-activity relationship of a new series of potent AT(1) selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles
    Almansa, C
    Gomez, LA
    Cavalcanti, FL
    deArriba, AF
    GarciaRafanell, J
    Forn, J
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (04) : 547 - 558
  • [37] First structure-activity relationship study on dopamine D3 receptor agents with N-[4-(4-arylpiperazin-1-yl)butyl]-arylcarboxamide structure
    Leopoldo, M
    Lacivita, E
    Colabufo, NA
    Contino, M
    Berardi, F
    Perrone, R
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (25) : 7919 - 7922
  • [38] HIV-1 X4 Activities of Polycationic "Viologen" Based Dendrimers by Interaction with the Chemokine Receptor CXCR4: Study of Structure-Activity Relationship
    Asaftei, Simona
    Huskens, Dana
    Schols, Dominique
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (23) : 10405 - 10413
  • [39] Design, synthesis, biological evaluation, and structure-activity relationship study of hydroxylated 2-phenyl-4-aryl indenopyridines as selective topoisomerase IIα inhibitor
    Kadayat, Tara Man
    Magar, Til Bahadur Thapa
    Bist, Ganesh
    Kwon, Youngjoo
    Lee, Eung Seok
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [40] STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF TXA(2) RECEPTOR ANTAGONISTS - 4-[2-(4-SUBSTITUTED PHENYLSULFONYLAMINO)ETHYLTHIO]PHENOXYACETIC ACIDS AND RELATED-COMPOUNDS
    KAWASHIMA, Y
    SATO, M
    YAMAMOTO, S
    SHIMAZAKI, Y
    CHIBA, Y
    SATAKE, M
    IWATA, C
    HATAYAMA, K
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1995, 43 (07) : 1132 - 1136